3RD FLOOR, ALTRINCHAM, CHESHIRE, X0
Ex-99.1
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Amended material disclosure
Announces CEO Transition as Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
Centessa Pharmaceuticals Enters Amended Sales Agreement with Leerink
Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
Reports Financial Results and Business Highlights for the Second Quarter of 2025
FY 2025
Q3
Q2
Q1
FY 2024
Amended Quarterly Report
Q3 amended
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Definitive Additional Information Statement
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
S-1MEF
SEC Staff Correspondence